In 2010, Hepalink’s A Shares were listed on the Shenzhen Stock Exchange.
We acquired SPL and Doppler in 2014 and 2018 respectively. Through a series of integration, we established a secure global supply chain, fully connected the entire heparin industry chain, becoming the world’s largest heparin API supplier, and the fourth largest supplier of enoxaparin finished doses globally. By broadening our portfolio of products, this allows us a sounder foundation and a stronger impetus for development.
After the scientific research achievements in the past decade, Hepalink has formed its unique logic of first-in-class layout. In terms of principle, we continue our R&D, exploration and investment in innovative drugs in the immumodulating field. Regarding disease entities, we focus more on cardiovascular and tumor diseases resulted from immunodulation imbalance. In terms of approaches, we push forward global R&D with a more effective and less risky way to ensure client interests, and meanwhile, we stick to and enhance our R&D strengths, especially for the R&D techniques focused on middle and late stage clinical drugs. We have chosen a pathway that highlights the complementary strengths of global cooperation and efficiency, which is also in line with Hepalink’s development interests.
To expand our selection scope of innovative drugs and enhance our precision in drugs selection to meet our drugs layout, and to accelerate the R&D pace of our current drug pipelines, Hepalink started looking for CDMO platforms globally since 2012, and successfully acquired Cytovance Biologics, Inc. in 2015. In addition, to follow the latest trend in biomacromolecule drug R&D technology, in 2016, we invested in Kymab, with which we make use of humanized mice and big data analysis technological platform to screen, develop and clinically transform the fully human antibody targeted at autoimmune diseases and cancer treatment.
Over the past decade, Hepalink has gradually become an innovation-driven international pharmaceutical company focusing on the heparin entire industry chain. Hepalink now has a multiple of cash flow businesses with steady growth, and a new drugs pipeline with dozens of First-in-Class innovative drugs.